| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Genomics Institute of the Novartis Research Foundation, San Diego, California 92121 [J. B. W., L. M. S., S. G. K., G. M. H.]; The Scripps Research Institute, La Jolla, California 92037 [A. I. S.]; Department of Pathology, University of California, San Diego, La Jolla, California 92093 [J. W-R.]; and Department of Pathology, University of Virginia, Charlottesville, Virginia 22908 [C. A. M., H. F. F.]
Detection, treatment, and prediction of outcome for men with prostate cancer increasingly depend on a molecular understanding of tumor development and behavior. We characterized primary prostate cancer by monitoring expression levels of more than 8900 genes in normal and malignant tissues. Patterns of gene expression across tissues revealed a precise distinction between normal and tumor samples, and revealed a striking group of about 400 genes that were overexpressed in tumor tissues. We ranked these genes according to their differential expression in normal and cancer tissues by selecting for highly and specifically overexpressed genes in the majority of cancers with correspondingly low or absent expression in normal tissues. Several such genes were identified that act within a variety of biochemical pathways and encode secreted molecules with diagnostic potential, such as the secreted macrophage inhibitory cytokine, MIC-1. Other genes, such as fatty acid synthase, encode enzymes known as drug targets in other contexts, which suggests new therapeutic approaches.
This article has been cited by other articles:
![]() |
K. A. Kelly, S. R. Setlur, R. Ross, R. Anbazhagan, P. Waterman, M. A. Rubin, and R. Weissleder Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent Cancer Res., April 1, 2008; 68(7): 2286 - 2291. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-K. Kim, J. J. Lee, Y. Yang, K.-H. You, and J.-H. Lee Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells Carcinogenesis, April 1, 2008; 29(4): 704 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. McCabe, D. D. Spyropoulos, D. Martin, and C. S. Moreno Genome-Wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer Cancer Res., March 15, 2008; 68(6): 1988 - 1996. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Wallace, R. L. Prueitt, M. Yi, T. M. Howe, J. W. Gillespie, H. G. Yfantis, R. M. Stephens, N. E. Caporaso, C. A. Loffredo, and S. Ambs Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men Cancer Res., February 1, 2008; 68(3): 927 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fritah, C. Saucier, O. De Wever, M. Bracke, I. Bieche, R. Lidereau, C. Gespach, S. Drouot, G. Redeuilh, and M. Sabbah Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells Mol. Cell. Biol., February 1, 2008; 28(3): 1114 - 1123. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Vavere, S. J. Kridel, F. B. Wheeler, and J. S. Lewis 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer J. Nucl. Med., February 1, 2008; 49(2): 327 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sauvageau, M. Miller, S. Lemieux, J. Lessard, J. Hebert, and G. Sauvageau Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia Blood, January 15, 2008; 111(2): 790 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. BANYARD, L. M. HUTCHINSON, and B. R. ZETTER Thymosin beta-NB Is the Human Isoform of Rat Thymosin beta15 Ann. N.Y. Acad. Sci., September 1, 2007; 1112(1): 286 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Oldberg, S. Kalamajski, A. V. Salnikov, L. Stuhr, M. Morgelin, R. K. Reed, N.-E. Heldin, and K. Rubin Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma PNAS, August 28, 2007; 104(35): 13966 - 13971. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Wong, H. Haack, J. L. Kissil, M. Barry, R. T. Bronson, S. S. Shen, C. A. Whittaker, D. Crowley, and R. O. Hynes Protein 4.1B suppresses prostate cancer progression and metastasis PNAS, July 31, 2007; 104(31): 12784 - 12789. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Bjartell, H. Al-Ahmadie, A. M. Serio, J. A. Eastham, S. E. Eggener, S. W. Fine, L. Udby, W. L. Gerald, A. J. Vickers, H. Lilja, et al. Association of Cysteine-Rich Secretory Protein 3 and {beta}-Microseminoprotein with Outcome after Radical Prostatectomy Clin. Cancer Res., July 15, 2007; 13(14): 4130 - 4138. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Tai and W. Pan Incorporating prior knowledge of predictors into penalized classifiers with multiple penalty terms Bioinformatics, July 15, 2007; 23(14): 1775 - 1782. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Song, J. Bedo, K. M. Borgwardt, A. Gretton, and A. Smola Gene selection via the BAHSIC family of algorithms Bioinformatics, July 1, 2007; 23(13): i490 - i498. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Selander, D. A. Brown, G. B. Sequeiros, M. Hunter, R. Desmond, T. Parpala, J. Risteli, S. N. Breit, and A. Jukkola-Vuorinen Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 532 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Turley, E. C. Finger, N. Hempel, T. How, T. A. Fields, and G. C. Blobe The Type III Transforming Growth Factor-{beta} Receptor as a Novel Tumor Suppressor Gene in Prostate Cancer Cancer Res., February 1, 2007; 67(3): 1090 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, L. M. Sapinoso, K. Ching, H. Frierson Jr., K. Brautigam, J. Sehouli, E. Stickeler, D. Konsgen, et al. An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 458 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Tozlu, I Girault, S Vacher, J Vendrell, C Andrieu, F Spyratos, P Cohen, R Lidereau, and I Bieche Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach Endocr. Relat. Cancer, December 1, 2006; 13(4): 1109 - 1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Knudsen Migrating with Myosin VI Am. J. Pathol., November 1, 2006; 169(5): 1523 - 1526. [Full Text] [PDF] |
||||
![]() |
T. Manoli, N. Gretz, H.-J. Grone, M. Kenzelmann, R. Eils, and B. Brors Group testing for pathway analysis improves comparability of different microarray datasets Bioinformatics, October 15, 2006; 22(20): 2500 - 2506. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Moran, W. Li, B. Fan, R. Vij, C. Eigenbrot, and D. Kirchhofer Pro-urokinase-type Plasminogen Activator Is a Substrate for Hepsin J. Biol. Chem., October 13, 2006; 281(41): 30439 - 30446. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Teschendorff, A. Naderi, N. L. Barbosa-Morais, and C. Caldas PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer Bioinformatics, September 15, 2006; 22(18): 2269 - 2275. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Madoz-Gurpide, P. Lopez-Serra, J. L. Martinez-Torrecuadrada, L. Sanchez, L. Lombardia, and J. I. Casal Proteomics-based Validation of Genomic Data: Applications in Colorectal Cancer Diagnosis Mol. Cell. Proteomics, August 1, 2006; 5(8): 1471 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J.M. Hendriksen, N. F.J. Dits, K. Kokame, A. Veldhoven, W. M. van Weerden, C. H. Bangma, J. Trapman, and G. Jenster Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer. Cancer Res., May 15, 2006; 66(10): 5012 - 5020. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Li, M. Szabolcs, J. D. Terwilliger, and A. Efstratiadis Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene Carcinogenesis, May 1, 2006; 27(5): 1054 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Liu, S. Ramachandran, M. Ali Seyed, C. D. Scharer, N. Laycock, W. B. Dalton, H. Williams, S. Karanam, M. W. Datta, D. L. Jaye, et al. Sex-determining region y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res., April 15, 2006; 66(8): 4011 - 4019. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-R. Li, J. Wang-Rodriguez, T. M. Nair, J. M. Yeakley, Y.-S. Kwon, M. Bibikova, C. Zheng, L. Zhou, K. Zhang, T. Downs, et al. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res., April 15, 2006; 66(8): 4079 - 4088. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-A. Xuan, D. Schneider, P. Toy, R. Lin, A. Newton, Y. Zhu, S. Finster, D. Vogel, B. Mintzer, H. Dinter, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res., April 1, 2006; 66(7): 3611 - 3619. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Vanaja, K. V. Ballman, B. W. Morlan, J. C. Cheville, R. M. Neumann, M. M. Lieber, D. J. Tindall, and C. Y.F. Young PDLIM4 Repression by Hypermethylation as a Potential Biomarker for Prostate Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1128 - 1136. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nanni, C. Priolo, A. Grasselli, M. D'Eletto, R. Merola, F. Moretti, M. Gallucci, P. De Carli, S. Sentinelli, A. M. Cianciulli, et al. Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer Mol. Cancer Res., February 1, 2006; 4(2): 79 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Duggan, W. M. Gallagher, E. J.P. Fox, M. M. Abdel-Latif, J. V. Reynolds, and D. Kelleher Low pH induces co-ordinate regulation of gene expression in oesophageal cells Carcinogenesis, February 1, 2006; 27(2): 319 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Vestergaard, M. Borre, S. S. Poulsen, E. Nexo, and N. Torring Plasma Levels of Trefoil Factors are Increased in Patients with Advanced Prostate Cancer Clin. Cancer Res., February 1, 2006; 12(3): 807 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Koopmann, C. N. W. Rosenzweig, Z. Zhang, M. I. Canto, D. A. Brown, M. Hunter, C. Yeo, D. W. Chan, S. N. Breit, and M. Goggins Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 Clin. Cancer Res., January 15, 2006; 12(2): 442 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Brown, C. Stephan, R. L. Ward, M. Law, M. Hunter, A. R. Bauskin, J. Amin, K. Jung, E. P. Diamandis, G. M. Hampton, et al. Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis Clin. Cancer Res., January 1, 2006; 12(1): 89 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X.-W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer Science, October 28, 2005; 310(5748): 644 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Berquin, Y. Min, R. Wu, H. Wu, and Y. Q. Chen Expression Signature of the Mouse Prostate J. Biol. Chem., October 28, 2005; 280(43): 36442 - 36451. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Tan, D. Q. Naiman, L. Xu, R. L. Winslow, and D. Geman Simple decision rules for classifying human cancers from gene expression profiles Bioinformatics, October 15, 2005; 21(20): 3896 - 3904. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Xu, A. C. Tan, D. Q. Naiman, D. Geman, and R. L. Winslow Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data Bioinformatics, October 15, 2005; 21(20): 3905 - 3911. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J.M. Best, J. W. Gillespie, Y. Yi, G. V.R. Chandramouli, M. A. Perlmutter, Y. Gathright, H. S. Erickson, L. Georgevich, M. A. Tangrea, P. H. Duray, et al. Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy Clin. Cancer Res., October 1, 2005; 11(19): 6823 - 6834. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, J. Yu, A. Sreekumar, S. Varambally, R. Shen, D. Giacherio, R. Mehra, J. E. Montie, K. J. Pienta, M. G. Sanda, et al. Autoantibody Signatures in Prostate Cancer N. Engl. J. Med., September 22, 2005; 353(12): 1224 - 1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Bauskin, D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, et al. The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcome Cancer Res., March 15, 2005; 65(6): 2330 - 2336. [Abstract] [Full Text] [PDF] |
||||
![]() |
D M Peehl Primary cell cultures as models of prostate cancer development Endocr. Relat. Cancer, March 1, 2005; 12(1): 19 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Santamaria, E. Castellanos, V. Gomez, P. Benedit, J. Renau-Piqueras, J. Morote, J. Reventos, T. M. Thomson, and R. Paciucci PTOV1 Enables the Nuclear Translocation and Mitogenic Activity of Flotillin-1, a Major Protein of Lipid Rafts Mol. Cell. Biol., March 1, 2005; 25(5): 1900 - 1911. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Baek, J.-S. Kim, F. R. Jackson, T. E. Eling, M. F. McEntee, and S.-H. Lee Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells Carcinogenesis, December 1, 2004; 25(12): 2425 - 2432. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Hobson, S. Netzel-Arnett, R. Szabo, S. M. Rehault, F. C. Church, D. K. Strickland, D. A. Lawrence, T. M. Antalis, and T. H. Bugge Mouse DESC1 Is Located within a Cluster of Seven DESC1-like Genes and Encodes a Type II Transmembrane Serine Protease That Forms Serpin Inhibitory Complexes J. Biol. Chem., November 5, 2004; 279(45): 46981 - 46994. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Nicholson, H. F. Frierson, M. R. Conaway, J. M. Seraj, M. A. Harding, G. M. Hampton, and D. Theodorescu Profiling the Evolution of Human Metastatic Bladder Cancer Cancer Res., November 1, 2004; 64(21): 7813 - 7821. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bibikova, D. Talantov, E. Chudin, J. M. Yeakley, J. Chen, D. Doucet, E. Wickham, D. Atkins, D. Barker, M. Chee, et al. Quantitative Gene Expression Profiling in Formalin-Fixed, Paraffin-Embedded Tissues Using Universal Bead Arrays Am. J. Pathol., November 1, 2004; 165(5): 1799 - 1807. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Jang, H. J. Kang, J. R. Kim, and C. H. Yang Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis Carcinogenesis, October 1, 2004; 25(10): 1853 - 1858. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Cheung, B. Woolcock, H. Adomat, M. Sutcliffe, T. C. Bainbridge, E. C. Jones, D. Webber, T. Kinahan, M. Sadar, M. E. Gleave, et al. Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis Cancer Res., September 1, 2004; 64(17): 5929 - 5933. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ashida, H. Nakagawa, T. Katagiri, M. Furihata, M. Iiizumi, Y. Anazawa, T. Tsunoda, R. Takata, K. Kasahara, T. Miki, et al. Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer: Genome-wide Gene-expression Profiles of Prostate Cancers and PINs Cancer Res., September 1, 2004; 64(17): 5963 - 5972. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E.H. Afar, V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer Mol. Cancer Ther., August 1, 2004; 3(8): 921 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Velasco, K. A. Gillis, Y. Li, E. L. Brown, T. M. Sadler, M. Achilleos, L. M. Greenberger, P. Frost, W. Bai, and Y. Zhang Identification and Validation of Novel Androgen-Regulated Genes in Prostate Cancer Endocrinology, August 1, 2004; 145(8): 3913 - 3924. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. P. Yu, D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, C. McDonald, R. Thomas, R. Dhir, S. Finkelstein, et al. Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy J. Clin. Oncol., July 15, 2004; 22(14): 2790 - 2799. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, and A. M. Chinnaiyan Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression PNAS, June 22, 2004; 101(25): 9309 - 9314. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sreekumar, B. Laxman, D. R. Rhodes, S. Bhagavathula, J. Harwood, D. Giacherio, D. Ghosh, M. G. Sanda, M. A. Rubin, and A. M. Chinnaiyan Humoral Immune Response to {alpha}-Methylacyl-CoA Racemase and Prostate Cancer J Natl Cancer Inst, June 2, 2004; 96(11): 834 - 843. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Rubin, S. Varambally, R. Beroukhim, S. A. Tomlins, D. R. Rhodes, P. L. Paris, M. D. Hofer, M. Storz-Schweizer, R. Kuefer, J. A. Fletcher, et al. Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer Cancer Res., June 1, 2004; 64(11): 3814 - 3822. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. RHODES and A. M. CHINNAIYAN Bioinformatics Strategies for Translating Genome-Wide Expression Analyses into Clinically Useful Cancer Markers Ann. N.Y. Acad. Sci., May 1, 2004; 1020(1): 32 - 40. [Abstract] [Full Text] [PDF] |
||||